FDA grants fast track status to Heidelberg Pharma’s Amanitin-based ADC candidate for multiple myeloma

The Fast Track Designation was supported by nonclinical data as well as clinical results from the ongoing Phase I/IIa trial evaluating the safety and tolerability

Sanofi’s Efdoralprin Alfa shows superiority in phase 2 Alpha-1 antitrypsin deficiency study

Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy

Gilead and Kite to transform cancer care with new data at ESMO 2025

The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy

MoS Health Patel inaugurates National Virus Research & Diagnostic Laboratory Conclave 2025

Launches National IVD validation portal and protocols; highlights India’s strengthening health research ecosystem

Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis

Eris Lifesciences receives ANVISA approval at its Ahmedabad campus

Sanofi’s GPRC5D monoclonal antibody earns ODD in US for multiple myeloma

Shilpa Pharma Lifesciences Unit-1 inspected by ANVISA

The audit has been concluded with no major observations

CCI approves merger between Aster DM Healthcare and Quality Care India

The merged entity ‘Aster DM Quality Care’ will be jointly controlled by Aster Promoters and Blackstone

Teva and Sanofi present new outcome from Phase 2b study of duvakitug

Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025